KeraMed Incorporated is the study sponsor of an FDA clinical study to evaluate the safety and probable benefit of the investigational KeraMed KeraKlear Keratoprosthesis (Keratoprosthesis means an artificial cornea) in the treatment of corneal blindness in patients with poor prognosis for corneal transplant. The study is currently being conducted at 4 clinical centers:
- Massachusetts Eye and Ear Infirmary Boston
- Cincinnati Eye Institute
- Duke University
- University of California Irvine
If you are interested in study participation, please contact Gretchen Neumann at email@example.com.
You will be compensated for your participation if you qualify as a study candidate. Please see the patient brochure which contains additional information regarding the KeraKlear Keratoprosthesis. Click here to view the brochure.